Articles dans des revues avec comité de lecture (11)
  1. 1. Dutour, R., & Bruylants, G. (2025). Gold Nanoparticles Coated with Nucleic Acids: An Overview of the Different Bioconjugation Pathways. Bioconjugate chemistry, 36(6), 1133-1156. doi:10.1021/acs.bioconjchem.5c00098
  2. 2. Nguyen, T. T. A., Dutour, R., Conrard, L., Vermeersch, M., Mirgaux, M., Perez-Morga, D., Baeyens, N., Bruylants, G., & Demeestere, I. (2025). Effect of Surface Modification of Gold Nanoparticles Loaded with Small Nucleic Acid Sequences on Cytotoxicity and Uptake: A Comparative Study In Vitro. ACS Applied Bio Materials, 8(4), 3040-3051. doi:10.1021/acsabm.4c01861
  3. 3. Gosselin, B., Dutour, R., Janssens, J., Jabin, I., & Bruylants, G. (2025). Repurposing Lateral Flow Assays as a Versatile and Rapid Characterization Tool for Bioconjugation of Nanoparticles. Bioconjugate chemistry, 36(3), 531-539. doi:10.1021/acs.bioconjchem.4c00589
  4. 4. Gosselin, B., Retout, M., Dutour, R., Troian Gautier, L., Bevernaegie, R., Herens, S., Lefèvre, P., Denis, O., Bruylants, G., & Jabin, I. (2022). Ultrastable Silver Nanoparticles for Rapid Serology Detection of Anti-SARS-CoV-2 Immunoglobulins G. Analytical chemistry, 94, 7383-7390. doi:10.1021/acs.analchem.2c00870
  5. 5. Dutour, R., Maltais, R., Perreault, M., Roy, J., & Poirier, D. (2019). Parallel Solid-Phase Synthesis using a New Diethylsilylacetylenic Linker and Leading to Mestranol Derivatives with Potent Antiproliferative Activities on Multiple Cancer Cell Lines. Anti-Cancer Agents in Medicinal Chemistry, 18(10), 1469-1481. doi:10.2174/1871520618666180307130158
  6. 6. Dutour, R., Roy, J., Cortés-Benítez, F., Maltais, R., & Poirier, D. (2018). Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity. Journal of medicinal chemistry, 61(20), 9229-9245. doi:10.1021/acs.jmedchem.8b00907
  7. 7. Dutour, R., Cortés-Benítez, F., Roy, J., & Poirier, D. (2017). Structure-Based Design and Synthesis of New Estrane–Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors. ACS Medicinal Chemistry Letters, 8(11), 1159-1164. doi:10.1021/acsmedchemlett.7b00265
  8. 8. Dutour, R., & Poirier, D. (2017). Inhibitors of cytochrome P450 (CYP) 1B1. European journal of medicinal chemistry, 135, 296-306. doi:10.1016/j.ejmech.2017.04.042
  9. 9. Perreault, M., Maltais, R., Roy, J., Dutour, R., & Poirier, D. (2017). Design of a Mestranol 2‐ N ‐Piperazino‐Substituted Derivative Showing Potent and Selective in vitro and in vivo Activities in MCF‐7 Breast Cancer Models. ChemMedChem, 12(2), 177-182. doi:10.1002/cmdc.201600482
  10. 10. Poirier, D., Roy, J., Cortés-Benítez, F., & Dutour, R. (2016). Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives. Bioorganic & medicinal chemistry letters, 26(21), 5272-5276. doi:10.1016/j.bmcl.2016.09.046
  11. 11. Perreault, M., Maltais, R., Dutour, R., & Poirier, D. (2016). Explorative study on the anticancer activity, selectivity and metabolic stability of related analogs of aminosteroid RM-133. Steroids, 115, 105-113. doi:10.1016/j.steroids.2016.08.015